脉络宁口服液联合尼麦角林对血管性痴呆患者氧化应激因子水平及认知功能障碍的影响

Effect of Mailuoning Oral Liquid Combined with Nicergoline on Levels of Oxidative Stress Factors and Cognitive Impairment in Patients with Vascular Dementia

目的探讨脉络宁口服液联合尼麦角林治疗血管性痴呆(VD)的疗效及对患者血浆同型半胱氨酸(HCY)、超敏C反应蛋白(hsCRP)及对氧磷酶1(PON1)水平和认知功能障碍的影响。方法选择医院2014年7月至2017年1月收治的血管性痴呆患者82例,按照随机数字表法分为对照组和观察组,各41例。对照组患者给予常规处理和尼麦角林治疗,观察组患者在对照组患者治疗基础上给予脉络宁口服液,两组患者均治疗12周。结果治疗后,观察组患者简易精神状态量表(MMSE)评分、长谷川痴呆量表(HDS)评分及血清超氧化物歧化酶(SOD)和PON1水平显著高于对照组(P<0.05),日常生活能力量表(ADL)评分及丙二醛(MDA),HCY,hs-CRP水平均显著低于对照组(P<0.05);观察组与对照组不良反应发生率无显著性差异(9.76%比7.32%,P>0.05)。结论脉络宁口服液联合尼麦角林治疗VD疗效显著,且可降低患者血浆HCY和hs-CRP水平,升高PON1水平,改善VD患者认知功能,值得临床推广。

Objective To investigate the effect of Mailuoning Oral Liquid combined with nicergoline on levels of plasma homocysteine（HCY）,hyper-sensitive C-reactive protein（hs-CRP）,paraoxonase 1（PON1） and the cognitive impairment in patients with vascular dementia（VD）.Methods Totally 82 patients with VD admitted to our hospital from July 2014 to January 2017 were selected and divided into the control group and the observation group according to the random number table method,41 cases in each group.The control group was given conventional treatment and nicergoline,on this basis,the observation group was given Mailuoning Oral Liquid.The two groups were treated for 12 weeks.Results After treatment,the mini-mental state examination（MMSE） score,Hasegawa＇s dementia scale（HDS） score,serum superoxide dismutase（SOD） level and PON1 level in the observation group were significantly higher than those in the control group（P〈0.05）,while the activity of daily living（ADL） score,malondialdehyde（MDA） level,Hcy level,hs-CRP level in the observation group were significantly lower than those in the control group（P〈0.05）.There was no significant difference in the incidence rate of adverse reactions between the two groups（9.76% vs.7.32%,P〉0.05）.Conclusion Mailuoning Oral Liquid combined with nicergoline is effective in the treatment of patients with VD,it can decrease the levels of plasma HCY and hs-CRP,increase the PON1 level and improve the cognitive function,which is worthy of clinical promotion.